S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.23
+1.55
+9.29%
JBIO · Jade Biosciences, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Jade Biosciences Inc (JBIO)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$15.12
+0.25
(+1.68%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$15.12
$14.87
$15.29
52-WEEK RANGE
$15.12
$8.36
$28.00
What's happening
- JBIO is up 1.68% today, trading at $15.12. — Live quote
- Volume today (52,406) is well below its 3-month average of 1,013,039. (Finnhub fundamentals)
- Reports earnings on 2026-11-11 (after market close), 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.76 actual vs. $-0.65 estimated (-17.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
JBIO
-1.94%
vs S&P 500
-15.31%
1-YEAR RETURN
JBIO
+50.85%
vs S&P 500
+35.68%
6-MONTH RETURN
JBIO
-33.79%
3-MONTH RETURN
JBIO
-23.78%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.76
Est. $-0.65
MISS -17.2%
2026-04-26 (Q1 2026)
$-0.57
Est. $-0.49
MISS -15.8%
2026-01-26 (Q4 2025)
$-0.59
Est. $-0.48
MISS -22.0%
2025-10-26 (Q3 2025)
$-0.48
Est. $-0.69
BEAT +30.2%
Valuation Measures & Ratios
Enterprise Value4$855.0M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book73.07
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-49.11%
Return on Assets (ROA9)-45.61%
Avg Volume (3M)1,013,039
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.63B | $993.3M | $449.7M | $372.3M | $28.6M |
| P/E | -10.62 | -7.31 | -4.02 | -3.34 | -0.28 |
| Price/Book | 3.70 | 3.35 | 2.51 | 1.85 | -0.34 |
| ROE | -34.88% | -45.82% | -62.31% | -55.25% | 122.63% |
| ROA | -32.50% | -42.53% | -55.20% | -49.72% | -132.08% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short12,119,108
Change from Prior Settlement+10.35%
% of Float—
Days to Cover (Short Ratio)11.33
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +50.8%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-09-30; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on JBIO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$58.9M | -$43.4M | -$27.4M | -$27.8M | -$23.4M | -$15.0M | -$26.2M | -$24.6M |
| Net income | -$55.8M | -$40.4M | -$25.2M | -$32.1M | -$38.2M | -$16.3M | -$24.8M | -$23.2M |
| EPS (diluted) | $-0.76 | $-0.57 | $-0.48 | $-0.86 | $-12.10 | $-5.16 | $-0.86 | $-0.83 |
| EPS (basic) | $-0.76 | $-0.57 | $-0.48 | $-0.86 | $-12.10 | $-5.16 | $-0.86 | $-0.83 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $472.1M | $319.4M | $349.8M | $202.4M | $224.0M | $77.5M | $72.8M | $91.0M |
| Total liabilities | $32.2M | $23.0M | $17.3M | $23.1M | $22.4M | $2.5M | $119.6M | $10.5M |
| Stockholders' equity | $439.9M | $296.5M | $332.5M | $179.3M | $201.6M | -$83.5M | -$46.8M | -$16.9M |
| Total current assets | $471.3M | $318.5M | $348.8M | $201.4M | $223.0M | $77.4M | $69.7M | $90.6M |
| Total current liabilities | $31.6M | $22.3M | $16.5M | $22.4M | $21.6M | $2.4M | $12.0M | $10.3M |
| Cash & equivalents | $107.2M | $55.1M | $88.4M | $50.1M | $220.9M | $44.2M | $69.4M | $31.1M |
| Marketable securities (current) | $354.0M | $256.2M | $247.7M | $148.8M | — | $32.0M | $0 | $57.6M |
| Property, plant & equipment | $144.0K | $157.0K | $170.0K | $176.0K | $147.0K | $2.0K | $0 | $14.0K |
| Other non-current assets | $69.0K | $69.0K | $69.0K | $174.0K | $60.0K | — | $3.1M | $81.0K |
| Accounts payable | $6.6M | $4.0M | $2.2M | $1.4M | $7.6M | $69.0K | $1.3M | $908.0K |
| Accrued liabilities | $14.9M | $14.9M | $9.4M | $14.0M | $8.1M | — | $4.1M | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $1.0K | $3.0K |
| Retained earnings | -$270.5M | -$214.8M | -$174.4M | -$142.5M | -$117.3M | -$235.6M | -$47.0M | -$227.6M |
| Accumulated other comprehensive income (loss) | -$660.0K | -$342.0K | $129.0K | $29.0K | -$24.0K | $50.0K | $0 | $224.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$43.7M | -$24.1M | -$33.6M | -$22.1M | -$20.2M | -$18.8M | -$15.8M | -$6.8M |
| Investing cash flow | -$97.6M | -$8.5M | -$98.2M | -$148.7M | -$13.0M | $12.8M | $47.2M | $0 |
| Financing cash flow | $193.5M | -$795.0K | $170.2M | $0 | $191.3M | -$700.0K | -$2.8M | $94.8M |
| Free cash flow | — | — | -$33.7M | -$22.2M | -$20.3M | — | — | — |
| Capital expenditures | — | — | $3.0K | $57.0K | $136.0K | — | — | — |
| Share-based compensation | $13.6M | $7.4M | $17.6M | $4.3M | $3.9M | $2.4M | $1.2M | $27.0K |
| Deferred income taxes | — | — | -$44.0K | — | — | — | — | — |
| Change in accounts payable | $2.1M | $2.3M | $301.0K | -$4.9M | $2.3M | $2.7M | $992.0K | $298.0K |
| Purchases of investments | $142.3M | $73.9M | $112.6M | $148.6M | — | — | — | — |
| Other financing activities | — | — | -$1.3M | $0 | $190.5M | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$113.5M | -$74.6M | -$81.4M | -$53.2M | -$23.0M |
| Net income | -$127.4M | -$69.6M | -$75.5M | -$51.5M | -$23.0M |
| EPS (diluted) | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-1.87 |
| EPS (basic) | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-1.87 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Jun '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|---|
| Total assets | $349.8M | $72.8M | — | $127.4M | $135.3M |
| Total liabilities | $17.3M | $119.6M | — | $18.0M | $8.6M |
| Stockholders' equity | $332.5M | -$46.8M | $1.0K | $109.5M | $126.7M |
| Total current assets | $348.8M | $69.7M | — | $124.2M | $131.5M |
| Total current liabilities | $16.5M | $12.0M | — | $17.6M | $7.8M |
| Cash & equivalents | $88.4M | $69.4M | — | $23.5M | $22.4M |
| Marketable securities (current) | $247.7M | $0 | — | $98.9M | $106.8M |
| Property, plant & equipment | $170.0K | $6.0K | — | $288.0K | $242.0K |
| Other non-current assets | $69.0K | $3.1M | — | $2.3M | $2.6M |
| Accounts payable | $2.2M | $1.3M | — | $2.4M | $2.6M |
| Accrued liabilities | $9.4M | $4.1M | — | — | — |
| Common stock & paid-in capital | $5.0K | $1.0K | — | $3.0K | $2.0K |
| Retained earnings | -$174.4M | -$47.0M | — | -$163.4M | -$87.9M |
| Accumulated other comprehensive income (loss) | $129.0K | $0 | — | $237.0K | -$466.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$94.7M | -$71.2M | -$56.8M | -$39.1M | -$27.4M |
| Investing cash flow | -$247.0M | $56.0M | $11.9M | $6.9M | -$113.4M |
| Financing cash flow | $360.8M | $25.4M | $46.0M | $396.0K | $190.5M |
| Free cash flow | -$94.9M | — | -$56.9M | -$39.3M | -$27.6M |
| Capital expenditures | $196.0K | — | $142.0K | $195.0K | $181.0K |
| Share-based compensation | $20.0M | $11.3M | $11.9M | $5.5M | $2.0M |
| Deferred income taxes | -$44.0K | — | — | — | — |
| Change in accounts payable | $361.0K | -$2.2M | -$164.0K | $1.4M | $609.0K |
| Purchases of investments | $261.2M | — | — | — | $113.3M |
| Other financing activities | $189.1M | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding JBIO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers105.9%
Shares Outstanding61,076,019
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| FMR LLC | 9,126,877 | $202.8M | 14.94% | +28.8% | 2026-08-13 |
| Jupiter Topco LLC | 6,273,262 | $139.4M | 10.27% | +0.0% | 2026-08-14 |
| Fairmount Funds Management LLC | 4,553,494 | $101.2M | 7.46% | +0.0% | 2026-08-14 |
| RA CAPITAL MANAGEMENT, L.P. | 3,671,083 | $81.6M | 6.01% | +0.0% | 2026-08-14 |
| Venrock Adviser, LLC | 3,220,364 | $71.6M | 5.27% | +0.0% | 2026-08-14 |
| Bellevue Group AG | 3,057,996 | $67.9M | 5.01% | -12.7% | 2026-08-13 |
| Paradigm Biocapital Advisors LP | 2,857,405 | $63.5M | 4.68% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 2,801,451 | $62.2M | 4.59% | +21.1% | 2026-08-07 |
| Franklin Templeton Inc | 2,792,080 | $62.0M | 4.57% | +0.0% | 2026-08-04 |
| State Street Corp | 2,335,285 | $51.9M | 3.82% | +256.2% | 2026-08-07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,244,773 | $49.9M | 3.68% | +24.9% | 2026-06-30 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,910,812 | $42.5M | 3.13% | +0.0% | 2026-08-14 |
| Polar Capital Holdings Plc | 1,846,982 | $41.0M | 3.02% | +0.0% | 2026-08-14 |
| Avidity Partners Management LP | 1,700,708 | $37.8M | 2.78% | +21.4% | 2026-08-14 |
| Remedium Capital Partners, LLC | 1,577,750 | $35.1M | 2.58% | +0.0% | 2026-08-07 |
| Soleus Capital Management, L.P. | 1,550,690 | $34.5M | 2.54% | +94.6% | 2026-08-11 |
| Jpmorgan Chase & Co | 1,475,079 | $32.6M | 2.42% | +9198.9% | 2026-08-12 |
| BAKER BROS. ADVISORS LP | 1,230,426 | $27.3M | 2.01% | -25.0% | 2026-08-14 |
| Logos Global Management LP | 1,125,000 | $25.0M | 1.84% | +181.2% | 2026-08-14 |
| Versant Venture Management, LLC | 991,783 | $22.0M | 1.62% | -35.0% | 2026-08-12 |
| ACORN CAPITAL ADVISORS, LLC | 986,760 | $21.9M | 1.62% | +25.4% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 985,178 | $21.9M | 1.61% | +19.8% | 2026-08-12 |
| CITADEL ADVISORS LLC | 929,407 | $20.7M | 1.52% | +577.3% | 2026-08-14 |
| Foresite Capital Management VI LLC | 886,667 | $19.7M | 1.45% | +177.1% | 2026-08-14 |
| BALYASNY ASSET MANAGEMENT L.P. | 878,726 | $19.5M | 1.44% | +118.3% | 2026-08-13 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-06-13 to 2026-02-12
Recent transactions
- Most recent: Dahms Bradford D. (Chief Financial Officer) — Grant / award of 37,813 shares on 2026-02-12.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Dahms Bradford D. | Chief Financial Officer | Grant / award | 2026-02-12 | 37,813 |
| Balta Elizabeth | See Remarks | Grant / award | 2026-02-12 | 28,125 |
| Frohlich Tom | Chief Executive Officer | Grant / award | 2026-02-12 | 78,750 |
| King Andrew James | See Remarks | Grant / award | 2026-02-12 | 41,250 |
| Fairmount Funds Management LLC | Director | Grant / award | 2025-10-06 | 1,333,126 |
| RA CAPITAL MANAGEMENT, L.P. | Reporting person | Other acquisition/disposition | 2025-04-28 | 1,062,326 |
| Dake Benjamin T | SEE REMARKS | Option exercise | 2024-08-01 | 1,507 |
| Eldridge George A | SEE REMARKS | Option exercise | 2024-06-14 | 15,000 |
| Verwijs Marinus | CHIEF TECHNICAL OFFICER | Option exercise | 2024-06-14 | 10,600 |
| Gillies Hunter | CHIEF MEDICAL OFFICER | Option exercise | 2024-06-13 | 6,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-02-12 | Dahms Bradford D. | Chief Financial Officer | Grant / award | 37,813 | $0.00 |
| 2026-02-12 | Balta Elizabeth | See Remarks | Grant / award | 28,125 | $0.00 |
| 2026-02-12 | Frohlich Tom | Chief Executive Officer | Grant / award | 78,750 | $0.00 |
| 2026-02-12 | King Andrew James | See Remarks | Grant / award | 41,250 | $0.00 |
| 2025-10-06 | Fairmount Funds Management LLC | Director | Grant / award | 1,333,126 | $9.14 |
| 2025-05-16 | Frohlich Tom | Chief Executive Officer | Open market purchase | 6,000 | $7.40 |
| 2025-04-28 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Other acquisition/disposition | 1,062,326 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:50 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-30 | 8-K | 2026-09-30 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-07-01 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-26 | 8-K | 2026-06-25 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-08 | View on SEC.gov → |
Recent news
Headlines about JBIO (Jade Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Jade Biosciences delays Phase 3 trial start for JADE101 By Investing.com
Investing.com Nigeria · 2026-10-21 -
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
Yahoo · 2026-10-21 -
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis - Slideshow
Seeking Alpha · 2026-09-30 -
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
Seeking Alpha · 2026-09-30 -
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Yahoo Finance · 2026-09-30 -
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha · 2026-09-09 -
Jade Biosciences to Participate in Upcoming Conferences
Yahoo Finance · 2026-09-01 -
Jade Biosciences: Duration Is The Real Product
Seeking Alpha · 2026-08-19
No headlines in this category right now — try “All”.